Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
To examine in a 3-year brain imaging study the effects of higher vs lower adherence to a Mediterranean-style diet (MeDi) on Alzheimer disease (AD) biomarker changes (brain β-amyloid load via <sup>11</sup>C-Pittsburgh compound B [PiB] PET and neurodegeneration via <sup>18</sup>F-fluorodeoxyglucose [FDG] PET and structural MRI) in midlife.
|
29653991 |
2018 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Regional analysis of relevant AD structures revealed reduction in <sup>18</sup>FDG retention in 5XFAD mice in all brain regions analyzed (save cerebellum) compared to WT<sub>5XFAD</sub>.
|
28729192 |
2017 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Correction: Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer's disease PET studies.
|
30883613 |
2019 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated the effect of a reduced acquisition time for <sup>18</sup>F-FDG PET studies of Alzheimer dementia (AD) and frontotemporal dementia (FTD) to derive a limit for reductions of acquisition time (improving patient compliance) and administered activity (lowering the radiation dose) with uncompromised diagnostic outcome.
|
31028167 |
2019 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Only a limited number of studies using <sup>18</sup>F-FDG-PET in AD mice were carried out so far showing contradictory findings in cerebral FDG uptake.
|
31058151 |
2019 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Education-Adjusted Normality Thresholds for FDG-PET in the Diagnosis of Alzheimer Disease.
|
29870998 |
2018 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The model was applied to FDG PET data of Alzheimer's disease (AD) and mild cognitive impairment (MCI) and clinical routine FDG PET data for assessing behavioral abnormality and seizures.
|
31003928 |
2019 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate longer-term prediction of MCI to AD conversion using 18F-FDG-PET and MRI in a multicenter study.
|
28922157 |
2017 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
While the sensitivity of <sup>18</sup>F-FDG PET to detect Alzheimer's disease is high, specificity is low and the additional use of biomarkers for amyloid deposition might be beneficial in some cases.
|
29512075 |
2018 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
the evaluation is done on ADNI dataset.The proposed method outperforms other state-of-the-art <sup>18</sup>F-FDG PET-based algorithms for AD vs. NC with an accuracy, a sensitivity and a specificity values of 93.65%, 91.22% and 96.25%, respectively.
|
31430595 |
2019 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, the goal of this study was to identify the combination of cerebrospinal fluid (CSF) biomarkers, MRI morphometry, FDG PET metabolism and neuropsychological test scores to that best differentiate between a sample of normal aging subjects and those with MCI and AD from the Alzheimer's Disease Neuroimaging Initiative.
|
29415470 |
2018 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Methods:</b><sup>18</sup>F-FDG PET scans of 544 MCI patients were obtained from the Alzheimer Disease Neuroimaging Initiative database and analyzed.
|
30389825 |
2019 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
FDG and rs-fMRI metrics distinguished aMCI/AD from controls according to spatial patterns analogous to those found in stand-alone studies.
|
29709628 |
2018 |
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The multivariate logistic model identified FDG-PET "AD" SPM classification (Expβ = 19.35, 95% C.I.
|
29387532 |
2018 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Discriminative performance (prodromal vs Alzheimer's disease dementia) of [<sup>18</sup>F]THK5317 (early-phase SUVr and R<sub>1</sub>) was compared with that of [<sup>11</sup>C]PIB (early-phase SUVr and R<sub>1</sub>) and [<sup>18</sup>F]FDG.
|
27107028 |
2017 |
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, <sup>18</sup>F-FDG PET and clinical assessments were collected in a cohort of 422 individuals [including 130 with AD, 130 with MCI, and 162 healthy controls (HCs)] from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and 44 individuals (including 22 with AD, and 22 HCs) from Huashan Hospital, Shanghai, China.
|
30956687 |
2019 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Metabolic Brain Network Analysis of FDG-PET in Alzheimer's Disease Using Kernel-Based Persistent Features.
|
31234358 |
2019 |
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This review aims to help readers understand the role of <sup>18</sup>F-FDG PET/CT imaging in the investigation of cognitive impairment and how the advent of amyloid PET/CT imaging may hold the key to radically changing management of the most common form of dementia - Alzheimer's disease.
|
30982329 |
2019 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
SPM analysis in AD patients showed a significant negative correlation between [<sup>18</sup>F] FBB and [<sup>18</sup>F] FDG uptake in temporal and parietal lobes bilaterally.
|
29404839 |
2018 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We assessed ninety-six subjects (27 cognitively normal, 49 mild cognitive impairment, and 20 AD dementia) who underwent [<sup>18</sup>F]FDG and [<sup>18</sup>F]Florbetapir positron emission tomography (PET) as well as magnetic resonance imaging (MRI) with diffusion tensor imaging.
|
30414086 |
2019 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>18</sup>F-FDG PET, the early phases and the delivery rate of <sup>18</sup>F-AV45 PET as proxies of cerebral blood flow in Alzheimer's disease: Validation against <sup>15</sup>O-H<sub>2</sub>O PET.
|
31405824 |
2019 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consecutive one-hundred and forty-three subjects with AD and 181 normal subjects who underwent both 18F-FDG PET and 18F-florbetapir (AV-45) PET at baseline were included to this study from the database of Alzheimer's disease neuroimaging initiative (ADNI).
|
27334941 |
2017 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
SNAP subjects show milder impairment of brain [<sup>18</sup>F] FDG uptake as compared to AD.
|
31201430 |
2019 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on different patterns of altered cerebral glucose metabolism, 18F-FDG PET was clinically used for differential diagnosis of AD and Frontotemporal dementia (FTD).
|
28671127 |
2017 |
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We included 38 patients with mild-to-moderate AD (mean age 67 ± 7 years, mean MMSE score 24 ± 4, mean years of education 14 ± 4; 20 men, 18 women) in whom a [<sup>18</sup>F]AV-1451 scan (a measure of tau pathology) and an [<sup>18</sup>F]FDG scan (a measure of neuronal function) were available.
|
31183635 |
2019 |